{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-052104","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2024-12-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.511901+00:00","generated_at":"2026-05-28T23:12:00.690489+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Elite Launches Generic Vyvanse (Lisdexamfetamine) in 7 Strengths for ADHD","bullets":["Elite launched generic lisdexamfetamine (Vyvanse) in 10, 20, 30, 40, 50, 60, 70 mg capsules.","Branded Vyvanse annual sales ~$4.3B (12 months ending Oct 2024, per IQVIA).","Product marketed under Elite Laboratories label; company operates cGMP/DEA facility in Northvale, NJ.","This generic version is indicated for treatment of attention deficit hyperactivity disorder (ADHD).","Launch represents expansion of Elite's niche generic product portfolio."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-052104","json":"https://secwatch.observer/filing/0001493152-24-052104.json","markdown":"https://secwatch.observer/filing/0001493152-24-052104.md","text":"https://secwatch.observer/filing/0001493152-24-052104.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315224052104/0001493152-24-052104-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315224052104/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T23:12:00.690489+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}